Skip to main content

Table 1 Summary of data on rates of resistant Pseudomonas aeruginosa

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author (Year) Country Setting Rates of resistance Ref.
NNIS (2004) USA ICU Imipenem resistance = 15% [18]
Quinolone resistance = 9%
3rd-generation cephalosporin resistance = 20%
Obritsch et al. (2004) USA ICU MDR P. aeruginosa (defined as resistance to at least three of the following four drugs: imipenem, ceftazidime, ciprofloxacin, and tobramycin) increased from 4% in 1993 to 14% in 2002 [19]
Morrow et al. (2013) USA Tertiary Doripenem resistance = 11.4% [20]
Imipenem resistance = 21.9%
Meropenem resistance = 15.4%
Levofloxacin resistance = 26.0%
Ceftazidime resistance = 15.2%
Tobramycin resistance = 10.1%
Piperacillin / tazobactam resistance = 14.7%
Souli et al. (2008), European Center for Disease Prevention and Control (2013) Europe Tertiary Carbapenem resistance = > 25% [21, 22]
De Francesco et al. (2013) Italy Tertiary MDR P. aeruginosa (defined as resistance to 5 commonly prescribed antibiotics) increased from 2.1% in 2007 to 4.1% in 2010 [23]
Joo et al. (2011) Korea Tertiary Ceftazidime resistance = 37% [24]
Piperacillin resistance = 22%
Imipenem resistance = 23%
Fluoroquinolone resistance = 24%
Aminoglycoside resistance = 18%
Gales et al. (2001) South America Tertiary MDR resistance = 8.2% [25]
Raja et al. (2001) Malaysia Tertiary MDR resistance = 6.9% [26]